Accession Number : ADA336728
Title : Novel Antiangiogenic/Cytotoxic Therapies for Advanced Breast Cancer.
Descriptive Note : Annual rept. 1 Sep 96-31 Aug 97
Corporate Author : HARVARD MEDICAL SCHOOL BOSTON MA
Personal Author(s) : Fett, James W.
PDF Url : ADA336728
Report Date : SEP 1997
Pagination or Media Count : 21
Abstract : It is now well documented that angiogenesis is required for the growth of both primary and metastatic breast cancer. Hence, inhibition of tumor-associated blood vessel growth should be an effective means of treating this disease. Our laboratory has investigated the structure/function relationships of a potent angiogenic mediator, termed angiogenin (Ang). Several inhibitors of its functions have been produced by us and shown previously to possess antitumor activity in preclinical models against a range of human solid tumor types. On this basis we were awarded a grant from the Department of Defense to extend our studies to the treatment of breast cancer. During the first year of funding we have developed reproducible models in athymic mice for the growth and metastatic spread of human breast cancer cell lines. We have shown that an antisense drug that targets Ang and an antiAng monoclonal antibody (mAb) inhibit establishment of estrogen-dependent and independent tumor cell lines in mice.
Descriptors : *CLINICAL MEDICINE, *CYTOTOXINS, *INHIBITION, *ANGIOGRAPHY, *BREAST CANCER, DEPARTMENT OF DEFENSE, HUMANS, NEOPLASMS, SOLIDS, POPULATION, THERAPY, TARGETING, PATIENTS, MICE, MONOCLONAL ANTIBODIES, INFECTIOUS DISEASES, CELLS(BIOLOGY), REPRODUCIBILITY, ANTIGENS, BLOOD VESSELS, MAMMARY GLANDS, METASTASIS.
Subject Categories : Anatomy and Physiology
Medicine and Medical Research
Distribution Statement : APPROVED FOR PUBLIC RELEASE